These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

449 related items for PubMed ID: 16625522

  • 21. [Treatment of anxiety with prazepam, 40 mg. A controlled study versus lorazepam].
    Danion JM, Brion S, Escande M, Ropert R, Sacquepee L, Singer L, Scotto JC.
    Encephale; 1984; 10(3):135-8. PubMed ID: 6389091
    [Abstract] [Full Text] [Related]

  • 22. Antianxiety effects of lorazepam in patients with cardiovascular symptomatology.
    Finkel S.
    J Clin Psychiatry; 1978 Oct; 39(10 Pt 2):35-40. PubMed ID: 30766
    [Abstract] [Full Text] [Related]

  • 23. Etifoxine is non-inferior than clonazepam for reduction of anxiety symptoms in the treatment of anxiety disorders: a randomized, double blind, non-inferiority trial.
    Vicente B, Saldivia S, Hormazabal N, Bustos C, Rubí P.
    Psychopharmacology (Berl); 2020 Nov; 237(11):3357-3367. PubMed ID: 33009629
    [Abstract] [Full Text] [Related]

  • 24. A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder.
    Woelk H, Schläfke S.
    Phytomedicine; 2010 Feb; 17(2):94-9. PubMed ID: 19962288
    [Abstract] [Full Text] [Related]

  • 25. [Clinical comparison between alprazolam and lorazepam. A polycentric study in double blind].
    Botte L, Bienfait J, Dethier J, Even P, Evrard JL, Fraipont J, Goffin L, Willemse P.
    Acta Psychiatr Belg; 1981 Feb; 81(6):595-608. PubMed ID: 6125089
    [Abstract] [Full Text] [Related]

  • 26. [A controlled double-blind study of tetrabamate versus lorazepam and placebo in generalized anxiety].
    Lôo H, Malka R, Hantouche E, Lancrenon S, Guelfi JD.
    Encephale; 1991 Feb; 17(4):295-300. PubMed ID: 1959498
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 28. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies.
    Pollack MH, Tiller J, Xie F, Trivedi MH.
    J Clin Psychopharmacol; 2008 Jun; 28(3):308-16. PubMed ID: 18480688
    [Abstract] [Full Text] [Related]

  • 29. Double-blind study of metaclazepam versus diazepam treatment of outpatients with anxiety syndrome.
    Laakmann G, Blaschke D, Hippius H, Schewe S.
    Pharmacopsychiatry; 1989 May; 22(3):120-5. PubMed ID: 2568645
    [Abstract] [Full Text] [Related]

  • 30. Adjunctive zonisamide for treatment refractory anxiety.
    Kinrys G, Vasconcelos e Sa D, Nery F.
    Int J Clin Pract; 2007 Jun; 61(6):1050-3. PubMed ID: 17504366
    [Abstract] [Full Text] [Related]

  • 31. A double-blind study of alprazolam and lorazepam in the treatment of anxiety.
    Ruiz AT.
    J Clin Psychiatry; 1983 Feb; 44(2):60-2. PubMed ID: 6131066
    [Abstract] [Full Text] [Related]

  • 32. A comparison of prazepam, diazepam, lorazepam and placebo in anxious outpatients in non-psychiatric private practices.
    Zung WW, Daniel JT, King RE, Moore DT.
    J Clin Psychiatry; 1981 Jul; 42(7):280-4. PubMed ID: 6113234
    [Abstract] [Full Text] [Related]

  • 33. [alpha-beta L-aspartate magnesium in treatment of chronic benzodiazepine abuse: controlled and double-blind study versus placebo].
    Hantouche EG, Guelfi JD, Comet D.
    Encephale; 1998 Jul; 24(5):469-79. PubMed ID: 9850822
    [Abstract] [Full Text] [Related]

  • 34. Double-blind placebo cross-over study of long-acting (chlordesmethyldiazepam) versus short-acting (lorazepam) benzodiazepines in generalized anxiety disorders.
    Bertin I, Colombo G, Furlanut M, Benetello P.
    Int J Clin Pharmacol Res; 1989 Jul; 9(3):203-8. PubMed ID: 2568350
    [Abstract] [Full Text] [Related]

  • 35. [Modification of cognitive functions by 2 anxiolytic treatments in patients suffering from generalized anxiety].
    Samuelian JC, Billardon M, Guillou N.
    Encephale; 1995 Jul; 21(2):147-53. PubMed ID: 7781586
    [Abstract] [Full Text] [Related]

  • 36. [Alprazolam versus lorazepam in the treatment of anxiety: controlled clinical study].
    Bernardi F, Fossi L, Faravelli C, Corsini GU, Varricchio MC.
    Riv Patol Nerv Ment; 1984 Jul; 105(1):1-13. PubMed ID: 6571441
    [Abstract] [Full Text] [Related]

  • 37. Comparative studies on the effects of the combination drug lorazepam plus diphenhydramine (Somnium) versus lorazepam on the noopsyche, thymopsyche and psychophysiology in nonorganic insomnia related to generalized anxiety disorder.
    Grünberger J, Saletu B, Linzmayer L, Böck G, Weissgram S, Brandstaätter N, Frey R, Saletu-Zyhlarz G.
    Methods Find Exp Clin Pharmacol; 1997 Nov; 19(9):645-54. PubMed ID: 9500129
    [Abstract] [Full Text] [Related]

  • 38. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.
    Rynn M, Russell J, Erickson J, Detke MJ, Ball S, Dinkel J, Rickels K, Raskin J.
    Depress Anxiety; 2008 Nov; 25(3):182-9. PubMed ID: 17311303
    [Abstract] [Full Text] [Related]

  • 39. Alpidem and lorazepam in the treatment of patients with anxiety disorders: comparison of physiological and psychological effects.
    Morton S, Lader M.
    Pharmacopsychiatry; 1992 Jul; 25(4):177-81. PubMed ID: 1356277
    [Abstract] [Full Text] [Related]

  • 40. Efficacy of kava-kava in the treatment of non-psychotic anxiety, following pretreatment with benzodiazepines.
    Malsch U, Kieser M.
    Psychopharmacology (Berl); 2001 Sep; 157(3):277-83. PubMed ID: 11605083
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.